AR107281A1 - PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP - Google Patents

PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP

Info

Publication number
AR107281A1
AR107281A1 ARP170100003A ARP170100003A AR107281A1 AR 107281 A1 AR107281 A1 AR 107281A1 AR P170100003 A ARP170100003 A AR P170100003A AR P170100003 A ARP170100003 A AR P170100003A AR 107281 A1 AR107281 A1 AR 107281A1
Authority
AR
Argentina
Prior art keywords
conjugate
gip
glp
prolonged
glucagon
Prior art date
Application number
ARP170100003A
Other languages
Spanish (es)
Inventor
Se Chang Kwon
Sung Youb Jung
Chang Ki Lim
Young Jin Park
Jong Suk Lee
Euh Lim Oh
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR107281A1 publication Critical patent/AR107281A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un conjugado representado por la fórmula química (1) a continuación: X-Lₐ-F (1) en la que, X es un péptido que tiene acciones en un receptor del glucagón, un péptido similar al glucagón tipo 1 (GLP-1) y un receptor polipéptido insulinotrópico dependiente de la glucosa (GIP); L es un conector; a es 0 o un entero positivo, con la condición que cuando a es 2 o mayor, cada L es independiente una de otra; y F es un material que puede aumentar la vida media de X. Reivindicación 23: Una composición farmacéutica para prevenir o tratar el síndrome metabólico que comprende un conjugado según cualquiera de las reivindicaciones 1 a 13. Reivindicación 24: La composición farmacéutica de la reivindicación 23, en la que el síndrome metabólico comprende intolerancia a la glucosa, hipercolesterolemia, dislipidemia, obesidad, diabetes, hipertensión, arteriosclerosis debido a la dislipidemia, ateroesclerosis, arteriosclerosis, o cardiopatía coronaria.Claim 1: A conjugate represented by the chemical formula (1) below: X-Lₐ-F (1) wherein, X is a peptide having actions at a glucagon receptor, a glucagon-like peptide type 1 (GLP) -1) and a glucose-dependent insulinotropic polypeptide receptor (GIP); L is a connector; a is 0 or a positive integer, with the proviso that when a is 2 or greater, each L is independent of each other; and F is a material that can increase the half-life of X. Claim 23: A pharmaceutical composition for preventing or treating metabolic syndrome comprising a conjugate according to any of claims 1 to 13. Claim 24: The pharmaceutical composition of claim 23 , in which the metabolic syndrome comprises glucose intolerance, hypercholesterolemia, dyslipidemia, obesity, diabetes, hypertension, arteriosclerosis due to dyslipidemia, atherosclerosis, arteriosclerosis, or coronary heart disease.

ARP170100003A 2015-12-31 2017-01-02 PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP AR107281A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150191082 2015-12-31

Publications (1)

Publication Number Publication Date
AR107281A1 true AR107281A1 (en) 2018-04-18

Family

ID=62104015

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170100004A AR107282A1 (en) 2015-12-31 2017-01-02 TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)
ARP170100003A AR107281A1 (en) 2015-12-31 2017-01-02 PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170100004A AR107282A1 (en) 2015-12-31 2017-01-02 TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)

Country Status (3)

Country Link
AR (2) AR107282A1 (en)
MA (4) MA42891B2 (en)
MY (1) MY199261A (en)

Also Published As

Publication number Publication date
MA53533A1 (en) 2022-08-31
MA42891B2 (en) 2021-11-30
AR107282A1 (en) 2018-04-18
MY199261A (en) 2023-10-23
MA51955A1 (en) 2021-10-29
MA42889B2 (en) 2020-11-30
MA51955B1 (en) 2022-04-29
MA42891A1 (en) 2019-04-30
MA42889A1 (en) 2018-11-30

Similar Documents

Publication Publication Date Title
PE20181494A1 (en) PERSISTENT CONJUGATE OF TRIPLE ACTIVATOR THAT ACTIVATES THE GLUCAGON RECEPTOR, GLP-1 U GIP
EA202090392A3 (en) GIP AND GLP-1 COAGONIST COMPOUNDS
DOP2021000273A (en) GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
CY1121423T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A METABOLIC SYNDROME
PE20210162A1 (en) INCRETINE ANALOGS AND THEIR USES
PE20211637A1 (en) GIP / GLP1 COAGONISTS COMPOUNDS
EA202091284A1 (en) INCRETIN ANALOGUES AND THEIR APPLICATION
BR112019011228A2 (en) compounds as peptide trigonal glp1 / glucagon / gip receptor agonists
MX2016015182A (en) Antidiabetic tricyclic compounds.
MX2015010935A (en) Antidiabetic bicyclic compounds.
BRPI0924307B8 (en) oxyntomodulin analogues
MX2019006427A (en) New compounds as peptidic glp1/glucagon/gip receptor agonists.
EA201890417A1 (en) GENETICALLY CODED, INTERNALLY DISORDERED "INVISIBLE" POLYMERES FOR DELIVERY AND THEIR APPLICATION METHODS
PH12015502547A1 (en) Anti-glucagon receptor antibodies and methods of use thereof
PE20220938A1 (en) GIPR AGONIST COMPOUNDS
PE20171622A1 (en) INSULIN GLARGIN / LIXISENATIDE FIXED RATIO FORMULATION
EA202191379A1 (en) COMBINED NAFLD AND NASH TREATMENT
DOP2022000122A (en) INCRETIN ANALOGS AND THEIR USES
AR107281A1 (en) PROLONGED CONJUGATE OF THE TRIGONAL GLUCAGON RECEIVER AGONIST / GLP-1 / GIP
BR112015003916A2 (en) peptide selected from the group consisting of peptide glp-1, peptide gip and their dipeptidyl peptidase iv (dpp-iv) resistant analogs; and pharmaceutical composition
EA202092891A1 (en) GIP / GLP1 COAGONISTS
MX2021007124A (en) Pharmaceutical composition containing insulin and glucagon.
TH172514A (en) Compounds work together GIP and GLP-1.
三村俊哉 Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis
EA201791296A1 (en) COMPOSITION WITH CONTINUOUS RELATIONSHIP INSULIN GLARGIN / LIKSENENID